Equillium Q2 FY26 net loss narrows to USD 4.7 million; cash slips to USD 57.2 million

• Equillium posted a net loss of USD 4.7 million, or USD 0.04 per share, in Q2 2026, narrowing from a USD 5.7 million loss.
• R&D expense fell 31.44% to USD 2.8 million, while G&A expense rose 12.17% to USD 2.4 million.
• Cash and cash equivalents totaled USD 57.2 million at June 30, 2026; management expects funding runway into 2029.
• Phase 1 proof-of-mechanism study of EQ504 is expected to start in Q4 2026, with topline data targeted about six months later.
• IND-enabling work began for inhaled EQ504 in inflammatory lung disease and for EQ302, an oral IL-15/IL-21 inhibitor for celiac disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809215) on August 13, 2026, and is solely responsible for the information contained therein.